Reversing muscle paralysis in critically ill patients
Effect of Neuromuscular Reversal Agents on Time for Neurological Assessment After Endotracheal Intubation in Critically Ill Patients
This study is testing whether different medications can help critically ill patients recover faster from muscle paralysis after being intubated.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 19 Years to 90 Years |
| Sex | All |
| Sponsor | Seoul National University Hospital Academic / other |
| Locations | 1 site (Seoul, Jongno-gu) |
| Trial ID | NCT05993390 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of different reversal agents for neuromuscular blockade in critically ill patients who have undergone endotracheal intubation. Participants will be randomly assigned to receive either sugammadex, neostigmine, or no medication, and the time taken for neurological assessment will be measured. The study will monitor the Glasgow Coma Scale (GCS) and other neurological indicators to determine the impact of these agents on recovery time. The goal is to identify which agent, if any, facilitates quicker neurological recovery.
Who should consider this trial
Good fit: Ideal candidates are adult patients aged 19 years or older who have been intubated in the intensive care unit.
Not a fit: Patients with pre-existing neurological dysfunction or neuromuscular disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to faster neurological assessments and improved outcomes for critically ill patients after intubation.
How similar studies have performed: Other studies have shown varying success with reversal agents for neuromuscular blockade, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients 19 years of age or older who were intubated after admission to the intensive care unit. Exclusion Criteria: * Patients younger than 19 years of age * Patients who are not neurologically evaluable or have concomitant neurologic dysfunction * Patients with neuromuscular disorder * Patients with a history of drug allergic reactions to sugammadex or neostigmine * Patients taking or planning to take toremifene, fusidic acid, or hormonal contraceptives
Where this trial is running
Seoul, Jongno-gu
- Seoul National University Hospital — Seoul, Jongno-gu, South Korea (Recruiting)
Study contacts
- Study coordinator: Leerang Lim, MD
- Email: erange@snu.ac.kr
- Phone: +82-10-5063-1742
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.